6 stories found
A diverse group of publicly traded firms, including retailers, biotech developers, and technology providers, have announced their participation in forthcoming investor conferences. These events will allow management teams to update shareholders on strategic initiatives and financial performance.
H.B. Fuller announced its fourth-quarter financial results, reporting a Non-GAAP EPS of $0.57, beating estimates by $0.02, while revenue of $771 million missed expectations by $14.01 million.
Analysts are expressing increased confidence in Equillium’s (EQ) lead asset, EQ504, suggesting positive outlooks for its development and potential.
Roth Capital has released its analysis and insights regarding the stock performance and outlook for Equillium (EQ).
Equillium announced a GAAP EPS of -$0.06, missing analyst estimates by $0.02 for the latest quarter.
Equillium's stock has surged following a $35 million financing deal secured from RA Capital Management, providing a significant boost to the company's financial position.